跳至主要内容
临床试验/NCT01614418
NCT01614418已完成1 期

Endoscopic Radiofrequency Ablation for Gastric Metaplasia and Dysplasia

The University of Hong Kong2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2011年9月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
10
试验地点
2
主要终点
Histological clearance of dysplasia/metaplasia

研究概览

简要总结

Gastric intestinal metaplasia (IM) and dysplasia, also referred to as intra-epithelial neoplasia, are well recognized precursors of gastric cancer. Apart from endoscopic surveillance, there is no other intervention which predictably eradicates pre-cancerous gastric lesions.

Endoscopic radiofrequency ablative (RFA) therapy has been recently shown to be highly effective in eradicating both IM and dysplasia in patients with Barrett's esophagus. However, the potential role of RFA to remove gastric IM and dysplasia remains unknown. In this study, we determine the feasibility of using endoscopic RFA in treating early gastric neoplasia (metaplasia and dysplasia). Patients with gastric metaplasia and/or dysplasia will be treated with endoscopic RFA. The safety and effects of RFA will be determined.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histological confirmation of gastric IM or dysplasia.
  • The lesion is no larger than 5 cm in diameter.
  • Age ≥ 18 years.
  • No previous endoscopic mucosal resection or submucosal dissection.
  • No active H. pylori infection.
  • Subject is able to tolerate endoscopy and sedation.
  • Subject agrees to participate, fully understands content of the informed consent, and signs the informed consent form.

排除标准

  • Gastric cancer (intra-mucosal cancer or worse).
  • Prior gastric irradiation or surgery.
  • Anti-platelet or anti-thrombotic medication use that cannot be stopped for 7 days before and after RFA.
  • Gastric ulcers, fistulae and varices.
  • History of alcohol and/or controlled substance dependency.

结局指标

主要结局

Histological clearance of dysplasia/metaplasia

时间窗: 6 month

次要结局

  • Number of Participants with Adverse Events(up to 6 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

LEUNG Wai Keung

Clinical Professor

The University of Hong Kong

研究点 (2)

Loading locations...

相似试验